Medical device company Cardiovascular Systems (CSI) has acquired the Wirion Embolic Protection System and related assets from Allium Medical Solutions’ wholly owned Israeli subsidiary Gardia Medical.
The Wirion System received the CE Mark in June 2015 and approval from the US FDA in March last year.
The easy-to-use distal embolic protection filter is used to capture debris that can be associated with all types of peripheral vascular intervention (PVI) procedures.
Wirion can be used with any .014” guidewire and for all types of peripheral interventions and is indicated for use with any atherectomy system.
Allium Medical Solutions CEO Asaf Alperovitz said: “We believe the Wirion System from Gardia Medical, one of our portfolio companies, will be highly synergistic with CSI’s growing portfolio of products.
“We will continue to partner with CSI to execute a timely manufacturing transfer and get the product in the hands of physicians.”
After the transfer of manufacturing from Gardia Medical, which is expected to be completed following a 12 to 15 month transition period, CSI plans to commercialise the device in the US.
The rights to the Wirion System for angioplasty and stenting procedures in the carotid arteries would be retained by Gardia.
CSI chairman, president and CEO Scott Ward said: “The acquisition of the Wirion System further supports our commitment and mission of building a comprehensive portfolio of differentiated products aimed at saving limbs and improving outcomes for patients undergoing complex peripheral interventions.”
An independent Filter Unit within the Wirion distal embolic protection system can be delivered, locked and deployed on marketed guide wires depending on physician preference in minimally invasive interventional procedures.